Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Nanotherapeutics in Cancer"
Deadline for manuscript submissions: closed (31 January 2020).
Interests: employing principles of nanomedicine in Ob/Gyn; targeting liver metastasis with advanced nanocarriers; novel strategies to target tumor microenvironment; advanced patient-derived ex vivo disease models for personalized therapies; exosomes
Tumor initiation, growth, and progression rely on the bidirectional interaction of the tumor cells with cellular and noncellular elements in the tumor microenvironment (TME). During the past two decades, extensive studies of the TME biology and its important role in disease progression and prognosis have provided a stage for the design of novel cancer nanomedicines. Significant aberrations in the TME as compared to the normal tissue, such as changes in the structure of the newly formed blood vessels, increased population of the immune cells, the acidic pH, alterations in the redox potential, and up- and down-regulation of membranal and secreted proteins, have ignited the research of passively targeted and stimulus-responsive nanomedicines for more efficient cancer diagnosis and therapy. Clinically used nanotherapeutics, such as liposomal doxorubicin (e.g., Doxil®) and nanoparticle-albumin bound paclitaxel (Abraxane®), utilize changes in the TME, such as the neovasculature-based enhanced permeation and retention (EPR) effect and increased albumin transport, to promote the delivery of chemotherapeutics to the tumor cells. More specific delivery of therapeutics to tumors using concepts of nanomedicine generally yields much better safety profiles and more efficient anti-cancer therapies. In the current Special Issue, entitled “Nanotherapeutics in Cancer”, we aim to cover a collection of current research papers and up-to-date review articles focusing on various aspects of the design of nanomedicines specifically targeted to enhance the safety and efficacy of tumor therapies.
Dr. Biana Godin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer nanomedicine
- tumor microenvironment
- tumor stroma
- targeted nanotherapies
- cancer nanomedicine
- enhanced permeation and retention effect
- targeting immune cells
- endothelial cells
- stimuli-responsive nanovectors